A Retrospective Clinical Comparison of Subtype Nonselective and Selective α<sub>1</sub>-Adrenoceptor Antagonists for Nocturia in Male Patients with Hypertension and Benign Prostatic Hyperplasia

Objectives: Hypertension and benign prostatic hyperplasia (BPH) can be major factors contributing to the occurrence of nocturia. Hypertension caused by an increase of daytime catecholamine levels would decrease renal blood flow, leading to insufficient daytime urine production. A relatively low levels of catecholamines at night would increase renal blood flow, allowing urine production to increase in order to excrete water stored during the daytime. The other main cause of nocturia is a low nocturnal bladder capacity due to BPH in male patients. Although doxazosin, a subtype nonselective α1-adrenoceptor antagonist, has been shown to improve hypertension and BPH, it is recommended that the 2 disease entities should be treated independently with the best available drugs. Therefore, we compared the efficacy and safety of 3 α1-adrenoceptor antagonists with different selectivity for the α1-adrenoceptor subtypes for nocturia in male patients with hypertension and BPH.